© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Long before people trusted high-tech medicine, bleeding posed a problem doctors couldn’t always solve. In the mid-20th century, researchers set out to tame unnecessary bleeding by looking at compounds that shape how blood vessels behave. Carbazochrome became part of this story. Born from the world of adrenochrome, scientists figured out how to tweak that parent compound by introducing a sodium sulfonate group, which improved water solubility and made it easier to inject or dissolve. Hospitals in Asia picked up on its use first, with Japan and China leading early investigations into whether it could slow or stop capillary bleeding. As it journeyed through decades of clinical trials and real-world pharmacy shelves, its story kept growing, gaining FDA acknowledgment for some use cases and turning into a mainstay in operating rooms in certain parts of the world.
Carbazochrome sodium sulfonate shows up as an orange-red crystalline powder that's ready for preparation as an injectable solution. Its unique structure comes from the addition of a sulfonic acid salt to a carbazochrome backbone, giving the molecule both water solubility and stability in solution. Most vials, ampoules, or tablets present labeled dosages specific to clinical needs, ranging from a few milligrams to higher loads depending on the scenario. Pharmacists keep it stocked on shelves intended for hospitals and some outpatient centers but its use often stays within specialized settings given its primary role in controlling microvascular or capillary bleeding.
Physically, carbazochrome sodium sulfonate stands out thanks to a vibrant orange-red color and its fine, crystalline structure. Dissolving it in water produces a clear, brightly colored solution—a detail that signals purity to trained eyes. The compound remains stable under standard conditions if protected from excess heat and light. In chemical terms, the molecular formula clocks in at C10H12N2NaO8S, with a molecular weight in the lower 300s. The extra sodium sulfonate group pulls in a higher level of polarity, helping it dissolve and mix cleanly into aqueous solutions for injection.
Labels never mess around with carbazochrome sodium sulfonate. Dosage, route (intravenous or intramuscular), batch number, and storage advice sit front and center, since errors in preparation can risk safety. Regulatory filings from Japan’s MHLW or China’s NMPA outline strict requirements: purity must exceed 98 percent, with low allowable levels for any related substances. Technicians stick to protocols when handling the powder, keeping vials away from light and moisture and always checking expiry and clarity before use. Each lot leaves the manufacturer with paperwork certifying analysis and batch testing—enough to keep compliance departments satisfied.
Manufacturing carbazochrome sodium sulfonate takes several tightly controlled steps. Synthetic chemists start with adrenochrome, then introduce the sulfonation reaction at lower temperatures to attach the sulfonic acid group at a chosen part of the molecule. After precise neutralization using sodium hydroxide, filters remove impurities. The crystallized product undergoes stringent purification and drying, followed by sterile filtration if destined for injectable recipes. I’ve watched teams pay close attention here, since even a trace of unreacted starting material or metal ions could compromise both stability and patient safety.
Chemically, the sulfonation of adrenochrome offers more than just solubility. It also lightens the molecule’s reactivity—limiting its potential for oxidative effects that could otherwise damage blood cells or tissues. Researchers stay curious about how its structure might shift with different acid or alkali treatments, sometimes tailoring derivatives for targeted delivery or slower breakdown in the body. Some teams even experiment with binding it to polymers or liposomes, hunting for an edge in controlling where and how it acts in the bloodstream.
People searching for this compound stumble on a handful of synonyms and commercial names. Some packaging uses "Adrenochrome Monosulfonate Sodium" or "Sodium Carbazochrome Sulfonate." Japan lists it as Adona, a brand so familiar that hospital staff instantly recognize it. Sometimes, older research reports use the simpler “carbazochrome sodium.” These names all circle back to the same therapy—reducing bleeding by capping small-vessel leaks.
Safety takes no shortcuts. Before use, nurses check for clear, particulate-free solutions and confirm that the patient isn’t allergic to any of the excipients. Side effects appear infrequently but need monitoring, including rare hypersensitivity or local irritation around injection sites. Regulatory agencies expect full track-and-trace documentation from bulk synthesis to final patient administration. Hospitals install strict procedures—trained teams mix doses in laminar flow hoods, follow double-checks, and discard any vials outside the recommended light or heat exposure. In my experience, accident-free use always comes down to communication and culture in the operating room.
Carbazochrome sodium sulfonate earns its keep when blood loss creeps outside normal limits but doesn’t call for transfusion. Surgeons use it during tonsillectomies, dental extractions, and gastrointestinal bleeding episodes to slow persistent oozing from small vessels. Obstetricians sometimes rely on it in early-stage postpartum hemorrhage, while hematologists incorporate it into strategies where capillary fragility drives risk. Some regional guidelines endorse its use, while outside Asia, doctors often learn to manage similar cases without it, relying on mechanical or alternative pharmacological control.
Investigators continue exploring how well carbazochrome sodium sulfonate performs versus newer hemostatic agents. Recent RCTs in Japan and Korea offer mixed results—its edge shows up mostly in outpatient or minor surgery settings, without strong signals for broad uptake in major trauma or surgery. Basic scientists look at molecular tweaks to boost selectivity or extend plasma life, hoping to address bleeding in aging populations or those on anticoagulant drugs. Some research teams experiment with combining it with growth factors, angling for a possible double-punch in wound healing. Publications track both biochemical effects—on endothelial cells, clotting factors, and platelet function—and patient outcomes, gathering an evidence base that keeps growing.
Toxicology groups have mapped out the safety margin for this compound. Acute toxicity studies in animals show a high threshold for adverse effects, with only mild symptoms at clinically relevant doses in most cases. Chronic use research comes up short, mainly since most patients receive it for a few days at most. Reports log rare allergic reactions, some mild headache or flushing, but life-threatening events remain exceptionally scarce. Good manufacturing practices minimize contamination risks—heavy metal, solvent residues, and bio-burden levels all meet global standards, supporting ongoing patient confidence and trust.
Next-generation forms of carbazochrome sodium sulfonate could tackle bleeding problems linked to new classes of anticoagulants or high-risk surgical populations. Researchers eye nanoformulations that target fragile vessels or damaged tissues while sparing healthy cells, aiming for more focused therapy. Regulatory push for new hemostatic solutions grows with broader surgical complexity and shortages of blood products worldwide. Interest in pre-hospital emergency use, including in battlefield or disaster medicine settings, drives fresh innovation. The question shifts from “Does it work?” to “How do we make it work better for more people, with fewer side effects and smarter delivery?”
Carbazochrome sodium sulfonate often pops up in hospital pharmacies, but most people outside medical fields haven't heard of it. It works as a hemostatic agent, which means doctors lean on it to control bleeding. In some countries, patients get a shot or a tablet containing this drug when blood loss runs above what seems normal during or after surgery, or sometimes after an injury. It’s been around for decades, and its main job is stopping capillary bleeding, which is the small-scale bleeding that can be tough to control.
Major blood loss worries doctors because it drags down oxygen supply, increases risk of shock, and slows healing. Minor bleeding may not draw instant attention, but repeat or lengthy bleeding eats away at the body’s resources and invites complications. In surgical settings, this can complicate procedures, lengthen operating times, and hike up costs. Any health care pro, whether surgeon, ER doctor or family physician, sees the value in tools that plug the loss, and drugs like carbazochrome sodium sulfonate offer another choice alongside more familiar agents.
Research over the years has delivered a mixed bag. Some studies suggest carbazochrome sodium sulfonate tampers down capillary bleeding in conditions like nosebleeds, gum bleeding, or after hemorrhoid surgery. It gets paired up in Asia with other remedies—aminomethylbenzoic acid, tranexamic acid—to curb overall blood loss in certain operations. The bulk of evidence says the effect feels mild compared with stronger clotting agents, so it’s no substitute for heavy hitters such as tranexamic acid, nor is it designed for open trauma. The World Health Organization and the FDA hold back from fully endorsing carbazochrome in national guidelines, mainly due to the shaky quality of evidence and limited improvement in outcomes.
Inside some Japanese, Chinese, and Russian hospitals, doctors still prescribe carbazochrome sodium sulfonate for minor bleeds. You won’t find it in every country, since licensing varies, and Western guidelines rarely mention it. In my own experience in a clinical setting, I’ve watched surgeons reach for it more due to habit or limited alternatives than shining clinical trials. Patients rarely see side effects, though allergic reactions and gut symptoms come up in reports.
For healthcare professionals, the bigger struggle revolves around access to up-to-date info. Many continue to use carbazochrome sodium sulfonate simply because it feels familiar or shows up on older hospital order sheets, not because recent research backs it. Pharmaceutical companies haven’t given it the attention bigger name drugs receive, so large-scale studies are rare, leaving many questions on the table.
To build trust and safer routines, health systems could invest in more training about bleeding control medications. Large comparative trials that include carbazochrome sodium sulfonate and newer agents would give everyone stronger evidence to act on. For now, it still fills a niche in a few parts of the world—useful for minor cases, but always second to proper surgical and trauma care. Patients expecting a miracle might instead find a modest but sometimes needed boost.
Carbazochrome sodium sulfonate, found in hospitals and clinics across Asia, draws the attention of healthcare workers for its promise in managing bleeding. Doctors prescribe it to stop nosebleeds, mouth bleeds, even bleeding in the gut. There’s a reason people reach for it: it steps in where clotting struggles. Yet most of us want to know, “Sure, it may stop bleeding—but what else comes with it?”
My days working with patients remind me that every drug stirs up something. Carbazochrome sodium sulfonate gets called “well-tolerated” in plenty of studies, but the body never lets anything walk in unnoticed.
Most often, people share stories of mild digestive trouble. Nausea shows up first—sometimes with stomach pain or diarrhea. These symptoms can pass in a few hours, but some patients would rather risk a minor bleed than deal with a rough stomach.
Rashes can appear. Doctors usually make allergy checks before starting this drug, but skin reactions tend to be unpredictable. I recall a patient breaking out in hives on her first dose, itching so badly she begged for something to make it stop. This kind of reaction can force an immediate switch to another medicine.
For those watching their heart, some cases mention palpitations or high blood pressure. Medical literature in Japan highlighted the possibility of hypertension right after an injection, particularly in older adults. Whether this drug causes high pressure or just nudges it higher in folks already close to the edge, the fact matters.
Nobody wants to think about allergic shock, but any injectable can trigger anaphylaxis. Tightness in the chest, trouble breathing—these symptoms come on fast. Emergency teams keep adrenaline handy for good reason.
Doctors and pharmacists rely on studies but learn even more from what patients share. In my practice, side effects usually crop up early. Many hospitals give the first dose with careful observation. Some patients never notice anything, while others ask for an immediate change. I’ve seen a patient halt treatment after severe cramping and sweats—hardly listed in textbooks, but impossible to ignore.
The path of this medicine in the body still brings questions. Pharmacokinetic data published in international journals tells us carbazochrome breaks down fast, so side effects tend to fade soon after stopping it. Still, dosing remains a delicate balance, especially for kids and elders.
Clinics and hospitals shape protocols around risk, not numbers alone. Before giving carbazochrome sodium sulfonate, modern guidelines ask about drug allergies and watch for chronic heart and kidney issues. Some clinics use test dosing, especially with children, just to cut down surprises.
Education works. Patients briefed on mild symptoms ask for help before problems grow. With my own patients, a quick check-in after the first injection uncovers discomfort that people sometimes keep quiet about.
Carbazochrome sodium sulfonate holds value in the right hands. Like anything sharp, it works best with respect, routine checks, and a willingness to pivot if the body pushes back.
References:Carbazochrome sodium sulfonate doesn’t turn up in everyday conversation, but it does show up in hospital pharmacies and operating rooms. Known for helping manage bleeding, it's typically trusted by surgeons and ER doctors trying to control small blood vessel bleeding. Based on my time around clinical teams, it gets called “AC-17” or just “carbazochrome”—rarely its full tongue-twister name.
Most of the time, carbazochrome sodium sulfonate comes as a clear injectable solution. Nurses draw it up into a regular syringe, check the dose with a colleague, and inject it directly into the patient’s muscle or vein. For muscle injections, the upper arm or thigh works best, especially for adults. Intravenous use, either as a slow push or a short infusion, happens in more urgent settings—bleeding that won’t stop after surgery or unexpected complications during childbirth.
In Japan and some other countries, it sometimes appears as part of a combination with other agents. There’s less reliance on it in the US or Western Europe, mainly because guidelines here put stronger weight on clinical trial data. But where it gets used, carbazochrome sodium sulfonate almost always travels via needle, not by mouth. There’s no pill—partly because stomach acid would break it down.
No drug fixes bleeding on its own. The idea with carbazochrome sodium sulfonate is to help shore up the walls of tiny blood vessels so they leak less. It's not a replacement for big solutions like surgery to stop an artery or giving blood transfusions when someone loses too much. From what I’ve seen, physicians use it as an add-on during nosebleeds, post-partum hemorrhage, or minor trauma—not as the solo answer.
Side effects don’t make headlines, though allergic reactions can happen, and in rare cases people develop rashes or low blood pressure. Responsible teams always watch patients after the shot. Sensible dosing matters too: going above the recommended dose has risks, and the information in published literature supports staying within strict limits. Over several decades, a few case reports flagged interactions with other clotting medicines, so thorough patient history comes first.
Bleeding is scary for families and hard to manage for care teams. Any tool—no matter how old—has value if used wisely. That said, real-world studies haven’t always shown a huge benefit from carbazochrome sodium sulfonate in big trauma or surgery cases. Japanese guidelines still mention it for minor bleeding, while the World Health Organization doesn’t list it among priority medicines.
Doctors and nurses get their best results by matching the right tool to the problem. Teaching new staff about risks and proven benefit saves confusion. Encouraging careful monitoring lets the team spot side effects fast. Institutions asking for published trial data before adding medications to their practice protect patient safety. My own view is that sharing experiences openly across countries paints a fuller picture of what works, especially when lives hang in the balance.
Doctors trust Carbazochrome Sodium Sulfonate to help stop bleeding from tiny blood vessels. I've seen how folks turn to this medicine, especially in countries across Asia thanks to its long track record. Still, just because a medication helps in some situations, doesn’t mean it works for everyone. I know from experience that a prescription can create new problems if underlying health issues go unnoticed.
Saying “Is it safe?” isn’t just doctor-speak. It gets personal when you’ve lived through a surprise side effect. I remember a neighbor dealing with a medication she thought was always reliable. Turns out, it paired badly with something in her medical history, so her doctor had to switch gears fast. Carbazochrome Sodium Sulfonate isn’t immune to this risk.
Some people face a bigger risk with Carbazochrome Sodium Sulfonate. Folks with allergies to it or similar chemicals need to steer clear. Allergic reactions aren’t just about feeling itchy; they can turn deadly. I once watched a healthcare worker react quickly when a patient broke out in hives-- a swift intervention saved the day.
Anyone with serious kidney troubles needs to check with their medical team before taking this drug. The body clears it through the kidneys, so people with slow kidney function may hang onto it longer. If old medicine builds up, it might do more harm than good. Serious kidney disease changes how the body reacts to almost every medication—this one included.
Kid safety also matters. Carbazochrome Sodium Sulfonate’s effects on babies and young kids haven’t seen wide research. Most doctors double and triple check before using anything off-label with children, and parents should always ask. Risking unproven treatments in young ones never makes sense.
Pregnancy brings another layer of caution. Enough solid studies on pregnant and breastfeeding people haven’t turned up. It’s not just about personal preference; it’s about protecting both mother and baby from possible side effects. Mothers deserve facts, and these facts just don’t exist yet.
Taking more than one medication isn’t rare, especially for those dealing with chronic health conditions. Doctors worry about interactions with blood thinners like warfarin—medicines designed to prevent blood clots. Carbazochrome Sodium Sulfonate, meant to stop bleeding, may reduce the effect of these drugs or make their side effects worse. This risk isn’t just theoretical; blood-thinner levels do jump or drop, and real harm can follow.
Even common over-the-counter remedies and certain supplements can mess with how drugs work. Full disclosure during check-ups stops bad surprises. I’ve watched a simple list of all the medicines a person takes save someone from a dangerous interaction more than once in the clinic.
No one wants to bleed longer than necessary. Still, rushing to a fix without careful checks does more harm than help. Good medicine comes from open talk with professionals who listen and share up-to-date info. Carbazochrome Sodium Sulfonate works for the right person at the right time. It takes skill to spot who fits that description—ignoring clear safety warnings never ends well.
Carbazochrome sodium sulfonate shows up in hospitals and clinics as a treatment for bleeding, especially in capillary vessels. Doctors rely on it to manage bleeding after surgery or trauma. The goal is clear: support blood vessel walls and control bleeding. Anyone prescribed this medication probably wonders how safe it is to mix with other drugs in everyday life.
Most folks taking carbazochrome sodium sulfonate already juggle several prescriptions or over-the-counter drugs. Mixing medicines can lead to problems, and the consequences can surprise even seasoned clinicians. Using any hemostatic agent, especially with drugs that change blood clotting or blood pressure, deserves close oversight. Anticoagulants, like warfarin or heparin, raise eyebrows for good reason. Combining these could backfire and blunt the effects both ways.
Looking at examples, pairing blood thinners with carbazochrome sodium sulfonate sends mixed messages to the body. One side tries to slow bleeding, the other keeps blood flowing. Some antibiotics, especially those impacting platelet function, also muddy the water. Aspirin and NSAIDs thin blood, making the work of carbazochrome sodium sulfonate tougher. If you have regular headaches or rely on ibuprofen for joint pain, that’s a detail your doctor must know.
I’ve seen people tell their doctor about every prescription in their cabinet but forget about supplements or herbal teas. St. John’s Wort and ginkgo biloba show up in health food stores, but they change how blood behaves, too. Anything that changes the way your body clots or breaks down drugs could cause trouble when added to the mix. In real-world practice, a full pharmacy list—including vitamins—saves hours of guesswork and unnecessary worry.
Hospitals often use electronic warning systems to flag risky drug combinations. But these systems rely on up-to-date records. Relying on memory can mean gaps. Communication between patients and medical teams sits at the core of safety here.
Thousands of folks end up in the emergency room every year because of medication interactions—many don’t know two common drugs can cause bleeding or even blood clots. Data from the Centers for Disease Control and Prevention shows nearly half of adults over 60 take multiple prescriptions daily. Mixing them carelessly puts health on the line.
Pharmacists serve as the final checkpoint for these problems. I’ve seen patients avoid major problems simply by chatting with a good pharmacist who spotted a bad combo at the checkout. Those with complicated medication lists should check in regularly with both their doctor and pharmacist, not just grab a refill and run.
Simple habits go a long way. Bring an updated medication list to every medical visit—include over-the-counter pills and herbal remedies. Ask pointed questions about every new prescription. If you hear about a new treatment online or from a neighbor, verify with a healthcare professional before trying anything.
Never stop or swap prescriptions based on internet stories. Doctors base choices on facts, not trends. If a reaction shows up—strange bruising, new nosebleeds, or sudden stomach pain—call for help instead of ignoring symptoms. Early action saves lives. Real peace of mind comes from honest, regular talks with people trained to catch these details.
| Names | |
| Preferred IUPAC name | sodium 8-chloro-7-hydroxy-2-methyl-3H-phenoxazine-5-sulfonate |
| Other names |
AC-17 Adrenochrome Monosulfonate Sodium Carbazochrome Sodiumsulfonate Carbazochrome Sodium Sulphate Sodium Carbazochrome Sulfonate |
| Pronunciation | /karˌbæz.oʊˈkroʊm ˈsoʊdiəm ˈsʌl.fəˌneɪt/ |
| Identifiers | |
| CAS Number | 51460-26-5 |
| Beilstein Reference | 3618739 |
| ChEBI | CHEBI:131264 |
| ChEMBL | CHEMBL2107681 |
| ChemSpider | 22943718 |
| DrugBank | DB09219 |
| ECHA InfoCard | 07a3a5e8-eed0-4911-abe0-6aabc4d209d0 |
| EC Number | 251-171-2 |
| Gmelin Reference | 119211 |
| KEGG | C02052 |
| MeSH | D002242 |
| PubChem CID | 23665441 |
| RTECS number | GE5950000 |
| UNII | T5QON5T8C3 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID4089481 |
| Properties | |
| Chemical formula | C10H11N3NaO8S2 |
| Molar mass | 496.51 g/mol |
| Appearance | Orange-red crystalline powder |
| Odor | Odorless |
| Density | 1.74 g/cm³ |
| Solubility in water | Very soluble in water |
| log P | -6.2 |
| Acidity (pKa) | 8.22 |
| Basicity (pKb) | 8.78 |
| Magnetic susceptibility (χ) | -8.0e-6 cm³/mol |
| Dipole moment | 2.86 D |
| Pharmacology | |
| ATC code | C05CX02 |
| Hazards | |
| Main hazards | May cause respiratory irritation. May cause eye irritation. May cause skin irritation. |
| GHS labelling | GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | No hazardous statements. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Store below 25°C (77°F). Protect from light. |
| NFPA 704 (fire diamond) | 1-0-0 |
| Lethal dose or concentration | LD50 (rat, intravenous): 380 mg/kg |
| LD50 (median dose) | LD50 (median dose): 156 mg/kg (intravenous, mouse) |
| NIOSH | Not Listed |
| REL (Recommended) | 0.2 mg/kg |
| IDLH (Immediate danger) | Not listed. |
| Related compounds | |
| Related compounds |
Adrenochrome Carbazochrome Adrenalone Chromonar Epinephrine |
